포인트 오브 케어 및 신속 진단 시장 : 2027년까지의 세계 예측

출판 : MarketsandMarkets(마켓츠앤드마켓츠)출판년월 : 2022년03월

제품[포도당, 감염증(HIV, C형 간염), 임신검사], 플랫폼(미세유체, 딥스틱), 구매방법(OTC, 처방전), 최종사용자(약국, 병원, 가정) – 2027년까지의 세계 예측

Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease(HIV, Hepatitis C), Pregnancy Test), Platform (Microfluidics, Dipsticks), Mode of Purchase (OTC, Prescription), End User (Pharmacy, Hospital, Home) – Global Forecast to 2027

페이지수 359
도표수 317
구성 영문조사보고서
가격

리포트목차    주문/문의    납기/라이센스안내

Sample Request

The global point of care diagnostics market is expected to reach USD 72.0 billion by 2027 from an estimated USD 43.2 billion in 2022, at a CAGR of 10.8% from 2022 to 2027.
전 세계 현장 진료 진단 시장은 2022년부터 2027년까지 CAGR 10.8%로 2022년 432억 달러에서 2027년 720억 달러에 이를 것으로 예상됩니다.

보고서 주요 목차

  • 요약
  • 프리미엄 인사이트
  • 시장 개관
  • 제품별 현장 진료 진단 시장
  • 플랫폼별 POC 진단 시장
  • 구매 방식에 따른 현장 진료 진단 시장
  • 최종 사용자에 의한 현장 진료 진단 시장
  • 지역별 현장 진료 진단 시장
  • 경쟁 구도
  • 회사 프로필
  • 부록
  • 테이블 목록

Point-of-care testing (POCT) includes screening or diagnostic tests performed outside traditional laboratories. These tests are designed to be used at or near the site where the patient is located (such as at home, in an ambulance, at a physician’s office, and other locations). POCT allows rapid and reliable diagnostic testing through which outcomes can be obtained instantly, helping physicians/patients to make decisions related to care remotely and as soon as possible. Market growth is mainly driven by the high prevalence of infectious diseases, supportive government policies and rising number of CLIA-waived POC tests. In addition, healthcare decentralization and greater investments and funding for product development are expected to offer growth opportunities for players in the point of care diagnostics market. POC tests can greatly improve the management of infectious diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse. According to UNAIDS, around 20.6 million people were living with HIV in East and Southern Africa in 2018. In 2019, 20,000 new HIV cases were registered in the Middle East and North Africa (Source: UNAIDS Data 2020). In the Asia Pacific, an estimated 5.8 million people were suffering from HIV in 2019, led by India and China. According to UNAIDS, in 2019, approximately 2.1 million people in India were infected with HIV. The high prevalence of HIV is likely to boost the demand for point-of-care diagnostics, further accelerating the treatment of HIV infection.

Listed below are important statistics related to major infectious diseases in developing countries:
According to the WHO, India has the highest tuberculosis burden, with an estimated incidence of 2.64 million cases in 2020.
• In 2019, around 4.3 million new tuberculosis cases were reported in Southeast Asia, and 632,000 people died due to TB infections in this region (Source: WHO).
• According to the National Influenza Policy 2017, around 10,000 deaths and 40,000 hospitalizations are caused due to influenza in South Africa each year.
• According to the WHO, 1.2 million people in Southeast Asia suffer from malaria, with India alone accounting for ~76% of the total malaria cases.
• During 2014–2016, West Africa reported the largest Ebola epidemic in the region; in two and a half years, the outbreak resulted in more than 28,600 cases and 11,325 deaths.
• In 2020, an estimated 15,898 people in Brazil were at risk of Zika virus infections, down from over 30,000 cases reported a year earlier.

The high prevalence of infectious diseases, coupled with the inadequate healthcare infrastructural facilities in developing countries, is expected to drive the adoption of POC testing.

“The Glucose Monitoring Products segment accounted for the largest share of the point of care diagnostics market, by product type, in 2021”

Based on products, the point-of-care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, COVID-19 testing products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, hematology testing products, tumor/cancer marker testing products, fecal occult testing products, urinalysis testing products, drug-of-abuse testing products, cholesterol testing products, and other products. In 2021, the glucose monitoring products segment accounted for the largest share of the point-of-care diagnostics market. This can be attributed to the growing diabetic patient population base, ongoing technological advancements, and the growing preference for home glucose testing.

“The Lateral Flow Assays segment accounted for the largest share of the point of care diagnostics market, by platform, in 2021”

Based on platform, the point-of-care diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics. The lateral flow assays segment accounted for the largest share of the market in 2021. The widespread adoption of lateral flow assays in POC testing as a replacement for lengthy, conventional laboratory procedures is a key factor contributing to the growth of this segment.

“The OTC Testing Products segment, by mode of purchase, accounted for the largest share of the global point of care diagnostics market in 2021”

On the basis of mode of purchase, the point-of-care diagnostics market is segmented into OTC testing products and prescription-based testing products. The OTC testing products segment accounted for the largest share of the market in 2021. The growing prevalence of lifestyle diseases and the favorable reimbursement scenario for OTC testing products are the major factors driving the growth of this market segment.

“On the basis of End Users, Hospitals & Critical Care Centers segment accounted for the largest share of the global point of care diagnostics market, in 2021”

On the basis of end users, the point-of-care diagnostics market is segmented into clinical laboratories; ambulatory care facilities and physicians’ offices; pharmacies, retail clinics, and E-commerce platforms; hospitals, critical care centers, and urgent care centers; home care & self-testing; and other end users. The hospitals & critical care centers segment is expected to dominate the market during the forecast period, owing to the increasing adoption of POC devices offering reduced turnaround time. The clinical laboratories segment accounted for the largest share of the point-of-care diagnostics market in 2021. However, the home care and self-testing segment is projected to register the highest CAGR during the forecast period, owing to the increasing prevalence of chronic diseases (requiring long-term care and frequent monitoring), growing awareness about home care, and the increasing availability of user-friendly and advanced POC diagnostic products.

“The Latin America market is expected to grow at the highest CAGR during the forecast period”

The global point of care diagnostics market is segmented into North America (comprising the US and Canada), Europe (includes Germany, France, and the UK), the Asia Pacific (includes Japan, China, India), Latin America (Brazil, Mexico), and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. The rising prevalence of lifestyle diseases, growing number of product approvals, and government initiatives to support the wider adoption of POC testing products are the key factors driving the growth of the North American point-of-care diagnostics market. On the other hand, the Latin American market is projected to register the highest growth during the forecast period due to government efforts to increase awareness about the early detection of diseases and regular health check-ups, further promoting point-of-care devices.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: C-level–10%, Director-level–14%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%

As of 2020, the point of care diagnostics market is dominated by Roche Diagnostics (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Quidel Corporation (US). Other leading players are Becton, Dickinson, and Company (US), Biomeriux S.A. (France), and Chembio Diagnostics (US).

Research Coverage

This report studies the point of care diagnostics market based on product type, platform, mode of purchase, end user and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
 Market Penetration: Comprehensive information on the product portfolios offered by the top players in the point of care diagnostics market
 Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the point of care diagnostics market
 Market Development: Comprehensive information on lucrative emerging regions
 Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the point of care diagnostics market
 Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.


목차

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 26)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 LIMITATIONS
1.6 KEY MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 32)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Indicative list of secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key industry insights
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 END-USER-BASED MARKET ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 COVID-19 HEALTH ASSESSMENT
2.4 COVID-19 ECONOMIC ASSESSMENT
2.5 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
2.6 DATA TRIANGULATION
2.7 RESEARCH ASSUMPTIONS & LIMITATIONS
2.7.1 ASSUMPTIONS FOR THE STUDY
2.8 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. – 46)

4 PREMIUM INSIGHTS (Page No. – 50)
4.1 POINT-OF-CARE DIAGNOSTICS MARKET OVERVIEW
4.2 IMPACT OF COVID-19 ON THE GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET (USD MILLION)
4.3 POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY MODE OF PURCHASE (2021)
4.4 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER AND COUNTRY (2021)
4.5 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION

5 MARKET OVERVIEW (Page No. – 54)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 High prevalence of infectious diseases
5.2.1.2 Increasing incidence of target conditions
5.2.1.3 Supportive government policies
5.2.1.4 Dearth of skilled laboratory technicians
5.2.1.5 Rising number of CLIA-waived POC tests
5.2.2 RESTRAINTS
5.2.2.1 Pricing pressure owing to reimbursement cuts and budget constraints
5.2.2.2 Stringent regulatory policies
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Healthcare decentralization
5.2.3.3 Increasing provider awareness about novel technologies
5.2.3.4 POC tests with multiplexing capabilities
5.2.3.5 Growing investments and funding for product development
5.2.4 CHALLENGES
5.2.4.1 Lack of alignment with definitive central lab methods
5.2.4.2 Inadequate adoption of POC devices in professional settings
5.2.4.3 Reluctance to change existing diagnostic practices
5.2.4.4 Premium pricing of novel platforms
5.3 TECHNOLOGY ANALYSIS: EMERGING POINT-OF-CARE APPLICATIONS
5.3.1 SEPSIS BIOMARKERS
5.3.2 STROKE/CARDIAC MARKERS
5.3.3 THYROID TESTING
5.3.4 DNA TESTING
5.3.5 ENDOCRINE TESTING
5.3.6 RESPIRATORY DIAGNOSTICS
5.4 REGULATORY LANDSCAPE
5.5 INDUSTRY TRENDS RELATED TO COVID-19
5.6 VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
5.7.1 PROMINENT COMPANIES
5.7.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.7.3 END USERS
5.8 PRICING TREND ANALYSIS
5.9 PORTER’S FIVE FORCES
5.9.1 OVERVIEW
5.9.2 BARGAINING POWER OF BUYERS
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 THREAT OF NEW ENTRANTS
5.9.5 THREAT OF SUBSTITUTES
5.9.6 INTENSITY OF COMPETITIVE RIVALRY
5.10 PATENT ANALYSIS

6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT (Page No. – 73)
6.1 INTRODUCTION
6.2 GLUCOSE MONITORING PRODUCTS
6.2.1 STRIPS
6.2.1.1 Strips make blood glucose testing easy and hassle-free
6.2.2 METERS
6.2.2.1 Blood glucose meters are extremely helpful in the monitoring of blood glucose levels and adjusting therapeutic regimens
6.2.3 LANCETS & LANCING DEVICES
6.2.3.1 Lancets & lancing devices segment to register lower growth in the glucose monitoring products market
6.3 COVID-19 TESTING PRODUCTS
6.3.1 ONGOING PANDEMIC HAS INCREASED THE DEMAND FOR POC DIAGNOSTIC PRODUCTS
6.4 CARDIOMETABOLIC MONITORING PRODUCTS
6.4.1 CARDIAC MARKER TESTING PRODUCTS
6.4.1.1 Rising government initiatives for CVD research will contribute to market growth
6.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
6.4.2.1 Technological advancements in blood gas/electrolyte products will drive the growth of this market segment
6.4.3 HBA1C TESTING PRODUCTS
6.4.3.1 Government initiatives are promoting the regular use of HbA1c testing
6.5 INFECTIOUS DISEASE TESTING PRODUCTS
6.5.1 HIV TESTING PRODUCTS
6.5.1.1 Rising prevalence of HIV to drive market growth
6.5.2 RESPIRATORY INFECTION TESTING PRODUCTS
6.5.2.1 POCT products for the diagnosis of respiratory infections offer lower sensitivity as compared to other tests
6.5.3 HEPATITIS C TESTING PRODUCTS
6.5.3.1 Central and East Asia are among the highly affected regions with Hepatitis C
6.5.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
6.5.4.1 Rising prevalence of HAIs is the key factor driving market growth
6.5.5 INFLUENZA TESTING PRODUCTS
6.5.5.1 Rising influenza prevalence has driven the demand for influenza testing products
6.5.6 TROPICAL DISEASE TESTING PRODUCTS
6.5.6.1 Increasing government funding for the use of POC in tropical disease testing will support market growth
6.5.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
6.5.7.1 Privacy and confidentiality issues are the key factors leading to the adoption of POC STD testing products
6.5.8 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
6.6 COAGULATION MONITORING PRODUCTS
6.6.1 PT/INR TESTING PRODUCTS
6.6.1.1 PT/INR is one of the most commonly used coagulation monitoring methods
6.6.2 ACT/APTT TESTING PRODUCTS
6.6.2.1 Rising number of patients undergoing angioplasty and dialysis globally to support market growth
6.7 PREGNANCY & FERTILITY TESTING PRODUCTS
6.7.1 PREGNANCY TESTING PRODUCTS
6.7.1.1 Rising inclination toward home testing to support market growth
6.7.2 FERTILITY TESTING PRODUCTS
6.7.2.1 Increasing awareness of fertility testing to drive market growth
6.8 TUMOR/CANCER MARKER TESTING PRODUCTS
6.8.1 INCREASING INVESTMENTS FOR RESEARCH RELATED TO POC CANCER TESTING ARE DRIVING MARKET GROWTH
6.9 DRUGS-OF-ABUSE TESTING PRODUCTS
6.9.1 RISING CONSUMPTION OF ILLICIT DRUGS HAS BOOSTED DEMAND FOR TESTING
6.10 FECAL OCCULT TESTING PRODUCTS
6.10.1 LACK OF PROPER TRAINING IN THE USE OF FECAL OCCULT TESTING TO HAMPER MARKET ADOPTION
6.11 OTHER PRODUCTS

7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM (Page No. – 134)
7.1 INTRODUCTION
7.2 LATERAL FLOW ASSAYS
7.2.1 INCREASING ADOPTION OF LFA TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET GROWTH
7.3 IMMUNOASSAYS
7.3.1 RISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH
7.4 MICROFLUIDICS
7.4.1 MICROFLUIDICS IS AN EMERGING PLATFORM IN THE POC DIAGNOSTICS MARKET
7.5 DIPSTICKS
7.5.1 DIPSTICKS HELP IN THE ROUTINE ANALYSIS OF SEVERAL MEDICAL CONDITIONS
7.6 MOLECULAR DIAGNOSTICS
7.6.1 INCREASING INITIATIVES BY MARKET PLAYERS FOR DEVELOPING POC MOLECULAR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH

8 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE (Page No. – 141)
8.1 INTRODUCTION
8.2 OTC TESTING PRODUCTS
8.2.1 RISING FOCUS ON HOME CARE HAS BOOSTED THE DEMAND FOR OTC TESTING PRODUCTS
8.3 PRESCRIPTION-BASED TESTING PRODUCTS
8.3.1 GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT HAVE DRIVEN MARKET GROWTH

9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER (Page No. – 145)
9.1 INTRODUCTION
9.2 CLINICAL LABORATORIES
9.2.1 IMPROVEMENTS IN CLINICAL DIAGNOSTICS AND TESTING TECHNOLOGIES WILL BOOST MARKET GROWTH
9.3 AMBULATORY CARE FACILITIES & PHYSICIANS’ OFFICES
9.3.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE ARE THE MAJOR FACTORS DRIVING MARKET GROWTH
9.4 PHARMACIES, RETAIL CLINICS, & E-COMMERCE PLATFORMS
9.4.1 CONVENIENCE AND EASE OF EXPERT ACCESS TO DRIVE MARKET GROWTH
9.5 HOSPITALS, CRITICAL CARE CENTERS, & URGENT CARE CENTERS
9.5.1 HOSPITALS ARE AMONG THE LARGEST END USERS OF POC DIAGNOSTICS
9.6 HOME CARE & SELF-TESTING
9.6.1 INCREASING INCLINATION TOWARD HOME HEALTHCARE IS DRIVING THE GROWTH OF THIS END-USER SEGMENT
9.7 OTHER END USERS

10 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION (Page No. – 153)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 The US dominates the North American POC diagnostics market
10.2.2 CANADA
10.2.2.1 Rising government initiatives to support the growth of the POC diagnostics market in Canada
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Germany accounts for the largest share of the European market
10.3.2 FRANCE
10.3.2.1 Growing public-private collaborations for product development to drive market growth
10.3.3 UK
10.3.3.1 Growing awareness of the benefits offered by POC diagnostics to support market growth in the UK
10.3.4 ITALY
10.3.4.1 Rising prevalence of chronic diseases in Italy to drive the demand for point-of-care diagnostics
10.3.5 SPAIN
10.3.5.1 Increasing funding for research in Spain to boost the market growth
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 JAPAN
10.4.1.1 Japan to dominate the APAC POC diagnostics market during the forecast period
10.4.2 CHINA
10.4.2.1 Rising investments by market players and the Chinese government to drive market growth
10.4.3 INDIA
10.4.3.1 High burden of chronic diseases to support market growth
10.4.4 AUSTRALIA
10.4.4.1 Government initiatives to support the adoption of point-of-care testing
10.4.5 SOUTH KOREA
10.4.5.1 Increased funding and product development to propel market growth
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 BRAZIL
10.5.1.1 Rising prevalence of diabetes to support market growth in Brazil
10.5.2 MEXICO
10.5.2.1 Rising prevalence of diabetes and cancer to support market growth in Mexico
10.5.3 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 RISING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH IN THE MEA

11 COMPETITIVE LANDSCAPE (Page No. – 232)
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.3 REVENUE SHARE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2021)
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.6 COMPETITIVE LEADERSHIP MAPPING: START-UP/SME EVALUATION QUADRANT (2021)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.7 COMPETITIVE BENCHMARKING
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES & APPROVALS
11.8.2 DEALS

12 COMPANY PROFILES (Page No. – 253)
12.1 KEY PLAYERS
12.1.1 F. HOFFMANN-LA ROCHE LTD.
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.4 MnM view
12.1.1.4.1 Right to win:
12.1.1.4.2 Strategic choices:
12.1.1.4.3 Strength and weaknesses:
12.1.1.4.4 COVID-19 impact:
12.1.2 ABBOTT
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.4 MnM view
12.1.2.4.1 Right to win:
12.1.2.4.2 Strategic choices:
12.1.2.4.3 Weakness and competitive threats:
12.1.2.4.4 COVID-19 impact:
12.1.3 SIEMENS HEALTHINEERS AG
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.4 MnM view
12.1.3.4.1 Right to win:
12.1.3.4.2 Strategic choices:
12.1.3.4.3 COVID-19 impact:
12.1.4 QUIDEL CORPORATION
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.5 DANAHER CORPORATION
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.4 MnM view
12.1.6 BECTON, DICKINSON AND COMPANY
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.6.3 Recent developments
12.1.6.4 MnM view
12.1.7 THERMO FISHER SCIENTIFIC
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.8 BIOMÉRIEUX S.A.
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.9 CHEMBIO DIAGNOSTICS, INC.
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.10 EKF DIAGNOSTICS
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.10.3 Recent developments
12.1.11 TRINITY BIOTECH PLC
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.11.3 Recent developments
12.1.12 INSTRUMENTATION LABORATORY (A WERFEN COMPANY)
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.12.3 Recent developments
12.1.13 NOVA BIOMEDICAL
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.13.3 Recent developments
12.1.14 PTS DIAGNOSTICS
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.14.3 Recent developments
12.1.15 SEKISUI DIAGNOSTICS
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.15.3 Recent developments
12.2 OTHER PLAYERS
12.2.1 LIFESCAN IP HOLDINGS, LLC
12.2.2 ASCENSIA DIABETES CARE HOLDINGS AG
12.2.3 FLUXERGY
12.2.4 PRESCISION BIOSENSOR, INC.
12.2.5 ACON LABORATORIES, INC.
12.2.6 A. MENARINI DIAGNOSTICS S.R.L
12.2.7 ORASURE TECHNOLOGIES, INC.
12.2.8 MANKIND PHARMA
12.2.9 TERUMO CORPORATION
12.2.10 GRIFOLS, S.A.
12.2.11 DIASORIN S.P.A.
12.2.12 ACCUBIOTECH CO., LTD.
12.2.13 MERIDIAN BIOSCIENCE
12.2.14 BIOCARTIS
12.2.15 GENESTAT MOLECULAR DIAGNOSTICS, LLC.

13 APPENDIX (Page No. – 336)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS

LIST OF TABLES (269 TABLES)

TABLE 1 STANDARD CURRENCY CONVERSION RATES
TABLE 2 RECENT WAIVERS FOR MARKET PRODUCTS
TABLE 3 AVERAGE PRICE OF GLUCOSE MONITORING AND CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2021 (USD)
TABLE 4 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2021 (USD)
TABLE 5 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2021 (USD)
TABLE 6 POINT-OF-CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 8 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 9 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 10 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 11 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 12 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 14 GLUCOSE MONITORING METERS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 15 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 16 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 17 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 18 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 20 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 21 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 22 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 23 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 24 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 25 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 26 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 27 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 28 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 29 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 30 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 31 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 32 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 33 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 36 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 38 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 40 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 41 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 44 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 45 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 46 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 47 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 48 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 49 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 50 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 52 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 53 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 54 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 55 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 56 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 57 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 58 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 59 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 60 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 61 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 62 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 63 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 65 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 66 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 67 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 68 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 69 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 70 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 71 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 72 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 73 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 74 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 76 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 77 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 78 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 79 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 80 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 81 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 82 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 83 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 84 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 85 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 86 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 87 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 88 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 89 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 90 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 91 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 92 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 93 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 94 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 95 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 96 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 97 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 98 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 99 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 100 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 101 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY END USER, 2020–2027 (USD MILLION)
TABLE 102 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 103 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 104 POINT-OF-CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2020–2027 (USD MILLION)
TABLE 105 POINT-OF-CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION)
TABLE 106 POINT-OF-CARE DIAGNOSTICS MARKET FOR MICROFLUIDICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 107 POINT-OF-CARE DIAGNOSTICS MARKET FOR DIPSTICKS, BY REGION, 2020–2027 (USD MILLION)
TABLE 108 POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 109 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 110 OTC POINT-OF-CARE TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 111 PRESCRIPTION-BASED POINT-OF-CARE TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 112 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 113 POINT-OF-CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 114 POINT-OF-CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIANS’ OFFICES, BY REGION, 2020–2027 (USD MILLION)
TABLE 115 POINT-OF-CARE DIAGNOSTICS MARKET FOR PHARMACIES, RETAIL CLINICS, & E-COMMERCE PLATFORMS, BY REGION, 2020–2027 (USD MILLION)
TABLE 116 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, & URGENT CARE CENTERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 117 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE & SELF TESTING, BY REGION, 2020–2027 (USD MILLION)
TABLE 118 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 119 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 120 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 121 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 122 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 123 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 124 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 126 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 127 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 128 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2018–2025 (USD MILLION)
TABLE 129 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 130 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 131 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 132 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 133 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 134 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 135 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 136 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 138 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 141 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 142 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 144 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 145 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 147 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 148 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 149 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 150 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 151 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 152 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 153 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 154 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 155 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 156 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 157 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 158 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 159 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 160 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 161 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 162 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 163 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 164 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 165 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 166 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 167 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 168 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 169 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 170 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 171 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 172 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 173 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 174 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 175 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 176 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 178 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 179 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 180 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 181 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 182 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 183 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 184 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 185 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 186 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 187 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 188 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 189 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 190 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 191 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 192 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 193 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 194 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 195 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 196 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 197 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 198 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 199 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 200 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 201 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 202 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 203 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 204 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 205 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 206 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 207 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 208 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 209 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 210 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 211 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 212 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 213 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 214 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 215 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 216 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 217 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 218 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 219 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 220 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 221 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 222 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 223 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 224 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 225 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 226 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 227 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 228 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 229 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 230 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 231 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 232 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 233 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 234 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 235 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 236 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 237 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 238 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 239 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 240 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 241 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 242 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 243 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 244 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 245 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 246 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 247 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 248 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 249 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 250 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION)
TABLE 251 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION)
TABLE 252 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 253 POINT-OF-CARE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
TABLE 254 COMPANY FOOTPRINT ANALYSIS IN THE POINT-OF-CARE DIAGNOSTICS MARKET
TABLE 255 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
TABLE 256 ABBOTT: BUSINESS OVERVIEW
TABLE 257 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
TABLE 258 QUIDEL CORPORATION: BUSINESS OVERVIEW
TABLE 259 DANAHER CORPORATION: BUSINESS OVERVIEW
TABLE 260 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
TABLE 261 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
TABLE 262 BIOMÉRIEUX S.A.: BUSINESS OVERVIEW
TABLE 263 CHEMBIO DIAGNOSTICS, INC.: BUSINESS OVERVIEW
TABLE 264 EKF DIAGNOSTICS: BUSINESS OVERVIEW
TABLE 265 TRINITY BIOTECH PLC: BUSINESS OVERVIEW
TABLE 266 INSTRUMENTATION LABORATORY: BUSINESS OVERVIEW
TABLE 267 NOVA BIOMEDICAL: BUSINESS OVERVIEW
TABLE 268 PTS DIAGNOSTICS: BUSINESS OVERVIEW
TABLE 269 SEKISUI DIAGNOSTICS: BUSINESS OVERVIEW

LIST OF FIGURES (42 FIGURES)

FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: POINT-OF-CARE DIAGNOSTICS MARKET
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 6 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 7 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
FIGURE 8 DATA TRIANGULATION METHODOLOGY
FIGURE 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021 VS. 2027 (USD MILLION)
FIGURE 10 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021 VS. 2027 (USD MILLION)
FIGURE 11 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021 VS. 2027 (USD MILLION)
FIGURE 12 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2027 (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE POINT-OF-CARE DIAGNOSTICS MARKET
FIGURE 14 RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET GROWTH
FIGURE 15 MARKET TO WITNESS A RISE DURING 2020–2021 OWING TO THE PANDEMIC
FIGURE 16 OTC TESTING PRODUCTS DOMINATED THE POINT-OF-CARE DIAGNOSTICS MARKET IN 2021
FIGURE 17 HOME CARE & SELF-TESTING IS THE LARGEST END-USER SEGMENT OF THE APAC POC DIAGNOSTICS MARKET
FIGURE 18 LATIN AMERICA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2022–2027)
FIGURE 19 POINT-OF-CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 20 VALUE CHAIN ANALYSIS—MAXIMUM VALUE IS ADDED DURING THE REGULATION AND DISTRIBUTION STAGES
FIGURE 21 SUPPLY CHAIN ANALYSIS
FIGURE 22 PATENT APPLICANTS FOR POINT-OF-CARE TESTING
FIGURE 23 PATENT APPLICANTS FOR POINT-OF-CARE DIAGNOSTICS
FIGURE 24 ECOSYSTEM COVERAGE: PARENT MARKET (IN VITRO DIAGNOSTICS)
FIGURE 25 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
FIGURE 26 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
FIGURE 27 KEY DEVELOPMENTS BY LEADING PLAYERS IN THE POINT-OF-CARE DIAGNOSTICS MARKET, JANUARY 2018–FEBRUARY 2022
FIGURE 28 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE POINT-OF-CARE DIAGNOSTICS MARKET
FIGURE 29 POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 30 POINT-OF-CARE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
FIGURE 31 POINT OF CARE MARKET: COMPETITIVE LEADERSHIP MAPPING (SMES/START-UPS) (2021)
FIGURE 32 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
FIGURE 33 ABBOTT: COMPANY SNAPSHOT (2021)
FIGURE 34 SIEMENS HEALTHCARE GMBH: COMPANY SNAPSHOT (2021)
FIGURE 35 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
FIGURE 38 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
FIGURE 39 BIOMÉRIEUX S.A.: COMPANY SNAPSHOT (2020)
FIGURE 40 CHEMBIO DIAGNOSTICS: COMPANY SNAPSHOT (2020)
FIGURE 41 EKF DIAGNOSTICS: COMPANY SNAPSHOT (2020)
FIGURE 42 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2020)


    주문/문의폼

    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.
    • 무료샘플은 구입 검토용으로만 의뢰해 주시길 부탁드립니다. 

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com